Peptides DB
Research-centric peptide and protocol reference hub

Tesamorelin record · updated 17h ago

Metabolic & appetiteSkin & aestheticsGrade A · human clinicalResearch use only
All 14 studiesJump to the evidenceCompare
What is Tesamorelin used for?

Tesamorelin is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog. It is primarily investigated for its potential to reduce visceral fat in individuals with HIV-associated lipodystrophy, a condition characterized by abnormal fat distribution often exacerbated by antiretroviral therapy. Tesamorelin stimulates the release of endogenous growth hormone, which in turn promotes lipolysis and reduces visceral adipose tissue (VAT) accumulation.

How it works: GHRH analog

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection

Development stage

where Tesamorelin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 15 registered trials. It describes the research record, not a recommendation.

Identity
NameTesamorelin
Chain length—
Molecular weight5,136 Da
FormulaC221H366N72O67S
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 16137828. No verified residue count for this compound.

Pharmacology
MechanismGHRH analog
RouteSubcutaneous injection
Half-life~26–38 min
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 29, 2026. How this works →
Research stats
Total studies14
Human / animal / cellular9 / 0 / 0
Highest trial phasePhase 4
Years covered2010–2026
Latest study4d ago
Publication history
20102026
Research funding
11 NIH projects · $7.3M awarded · through FY2025
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports19
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

14 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
Finding-24 +/- 41 cm(2) VAT reduction in tesamorelin vs 2 +/- 35 cm(2) in placebo at 26 wk, P < 0.001.
Human2010Full text read0.90
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.
FindingNot reported in abstract.
review2012Full text read0.80
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
TakeawayThe TRIUMPH study is examining whether tesamorelin combined with exercise can improve physical function in older adults living with HIV, but results are not yet available.
Human2026Partial text0.50
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
FindingNot reported in abstract.
Human2026Full text read0.80
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
Finding-34 cm2 mean change in visceral adipose tissue with tesamorelin vs 8 cm2 with placebo; P=0.005.
Human2014Full text read0.90
Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.
FindingNot reported in abstract.
Human2021Full text read0.80
The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging.
FindingCAP scores: 241.8 ± 50.0 dB/m in acromegaly patients, 281.7 ± 61.2 dB/m in metabolically matched controls, p < 0.001.
Human2026Full text read0.80
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
TakeawayThe TRIUMPH study will explore the effects of tesamorelin combined with exercise on physical function in older adults living with HIV, but results are not yet available.
Human2026Partial text0.50
The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.
FindingNot reported in abstract.
Human2026Full text read0.70
Maraviroc with or Without Metformin for the Treatment of Non-Alcoholic Fatty Liver Disease in Virologically Suppressed Adults with HIV (MAVMET)
FindingMean PDFF at week 48 was 12.9% (SD 9.0), n=82.
Human2023Full text read0.90
Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
FindingMD=-27.71 cm² visceral adipose tissue reduction, 95% CI [-38.37, -17.06]; P<0.001
review2026Full text read0.80
Semantic Scholar search for Tesamorelin
TakeawayNot reported in abstract.
—2010Title only0.00

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Tesamorelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Tesamorelin is discussed should be drawn from it.

Articles mentioning Tesamorelin